Ryo Iwamura

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.

Naveed B K Shams, Noriko Odani-Kawabata, K. Yamamura, 2018, Investigative ophthalmology & visual science.

Glaucoma Pharmacologic Characterization of Omidenepag Isopropyl , a Novel Selective EP 2 Receptor Agonist , as an Ocular Hypotensive Agent

Naveed B K Shams, Noriko Odani-Kawabata, K. Yamamura, 2018 .

Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type Gi‐linked P2T antagonist, CS‐747

H. Koike, T. Ogawa, K. Otsuguro, 2001, British journal of pharmacology.

Identification of the active metabolite of ticlopidine from rat in vitro metabolites

Sei Kobayashi, Y. Mizukami, H. Kishi, 2004, British journal of pharmacology.

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.

Naveed B K Shams, Noriko Odani-Kawabata, R. Iwamura, 2018, Journal of medicinal chemistry.

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells

Y. Sugimoto, Naveed B K Shams, Tomoaki Inazumi, 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.

M. Fuwa, C. Toris, Naveed B K Shams, 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.